Olio Labs

Olio Labs is an AI simulation generator tool. A drug discovery platform that models interacting layers of biology to propose combination therapies, ranks them by expected benefit and side-effect burden, then screens top candidates in a high-throughput in vivo phenomics pipeline.

Olio Labs is a drug discovery platform built around what it calls the Combination Design Engine. Rather than searching for single targets in isolation, the company models several interacting layers of biology at once and asks which set of interventions produces a desired response while holding unwanted effects down. The output is a ranked list of predicted combination therapies, ordered by expected benefit and expected side-effect burden. That framing puts Olio closer to a computational discovery shop than to a conventional screening vendor. The pipeline has three connected stages. It begins with human drug-response data, curated with custom human-in-the-loop agentic tools, which is used to train and refine each algorithm. From there, target discovery generates candidate combinations. Top candidates then move into a high-throughput in vivo phenomics platform built on rodent models, where custom models drawing on behavioral datasets predict human efficacy, safety and tolerability. Olio states that an experiment in this stage runs in 24 hours, which is the clearest signal of how quickly predictions can be tested rather than assumed. The intended users are research groups and drug developers evaluating combination strategies, particularly teams that need evidence tied to human outcomes rather than purely in silico rankings. Working with the platform is less a self-serve software exercise and more a research engagement: you bring a disease area or a response you want to achieve, and the system proposes and ranks intervention sets that are then screened in vivo. Among alternatives, Olio differentiates on two claims: human data anchoring every model, and a wet-lab validation loop attached to the computational layer. Teams comparing it with target discovery software or with contract research organizations should weigh the value of an integrated discovery-to-validation chain against the tradeoffs below.